Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06355310 · ClinicalTrials.gov registry record · Phase 2
Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease
A Phase 2 study of Non-alcoholic Fatty Liver Disease, sponsored by Justin Ryder.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06355310: Recruiting Phase 2 study of Non-alcoholic Fatty Liver Disease, sponsored by Justin Ryder.
NCT06355310 is a Phase 2 study of Non-alcoholic Fatty Liver Disease that is actively recruiting participants, run by Justin Ryder. The registered enrollment target is 40 participants, below the 177-participant average among 57 other Non-alcoholic Fatty Liver Disease trials with a reported enrollment target (77% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06355310, a Phase 2 study of Non-alcoholic Fatty Liver Disease, is actively recruiting participants, sponsored by Justin Ryder.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
This study is a randomized, double-blind, placebo-controlled trial specifically designed to evaluate the preliminary feasibility, initial efficacy and safety of SGLT2 inhibitors for treating NAFLD in adolescents with obesity.
Primary Outcome
change in hepatic fat fraction (Hepatic fat will be measured by MRI via proton density fat fraction (PDFF)) from baseline (first measurement time point) to 26-weeks.
Conditions Studied
Interventions
- DRUG Empagliflozin 10 MG
- DRUG Placebo Oral Tablet
Study Locations (1)
Illinois
- Ann & Robert H Lurie Children's Hospital of Chicago - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2025-04-10 |
| Est. Completion | 2028-02-01 |
| Phase | Phase 2 |
What NCT06355310 shows while recruiting
NCT06355310 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 177-participant average among 57 other Non-alcoholic Fatty Liver Disease trials with a reported enrollment target (77% lower).
The record links to 1 condition, with Non-alcoholic Fatty Liver Disease appearing as the primary indexed condition, and to 2 interventions - of which Empagliflozin 10 MG is the first listed.
NCT06355310 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT06355310 about?
NCT06355310 is a clinical study titled "Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease". This study is a randomized, double-blind, placebo-controlled trial specifically designed to evaluate the preliminary feasibility, initial efficacy and safety of SGLT2 inhibitors for treating NAFLD in adolescents with obesity.
What is the current status of trial NCT06355310?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2025-04-10. Estimated completion is 2028-02-01.
What conditions does trial NCT06355310 study?
This clinical trial studies the following conditions: Non-alcoholic Fatty Liver Disease.
What interventions are being tested in trial NCT06355310?
The interventions under investigation include: Empagliflozin 10 MG (DRUG), Placebo Oral Tablet (DRUG).
Who is sponsoring clinical trial NCT06355310?
This trial is sponsored by Justin Ryder, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06355310 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-alcoholic Fatty Liver Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06355310's enrollment target sits among peer trials
40 40th of 57 higher than 15 of 57 other Non-alcoholic Fatty Liver Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-alcoholic Fatty Liver Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Non-Alcoholic Fatty Liver Disease, the HEpatic Response to Oral Glucose, and the Effect of Semaglutide (NAFLD HEROES)
RECRUITING · Phase 2
-
Semaglutide Effects in Obese Youth With Prediabetes/New Onset Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease
RECRUITING · Phase 2
-
Impact of Soymilk on Liver Disease Severity of Children With Non-alcoholic Fatty Liver Disease (NAFLD)
RECRUITING · Phase 2
-
A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
ACTIVE NOT RECRUITING · Phase 2
-
Phase 2b Study of GSK4532990 in Adults With NASH
ACTIVE NOT RECRUITING · Phase 2
-
MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI